Publications by authors named "I Hardan"

Claim this Profile
A
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
R Hájek, T Masszi, M T Petrucci, A Palumbo, L Rosiñol, I Hardan

Leukemia· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
Merav Leiba, Adrian Duek, Ninette Amariglio, Abraham Avigdor, Noam Benyamini, Izhar Hardan

Genes Chromosomes Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
Moshe E Gatt, Izhar Hardan, Evgeni Chubar, Celia Suriu, Tamar Tadmor

Eur J Haematol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Antonio Palumbo, Francesca Gay, Federica Cavallo, Francesco Di Raimondo, Alessandra Larocca, Izhar Hardan

J Clin Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
Amnon Peled, Michal Abraham, Irit Avivi, Jacob M Rowe, Katia Beider, Izhar Hardan

Clin Cancer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis